In This Article:
In a week marked by fluctuations on the ASX200 and the much-anticipated listing of DigiCo, Australian investors are closely watching market trends and sector performances. Amid these movements, growth companies with high insider ownership present intriguing opportunities, as they often signal strong confidence from those closest to the business in navigating challenging economic landscapes.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| SKS Technologies Group (ASX:SKS) | 27% | 24.8% |
| Medallion Metals (ASX:MM8) | 13.8% | 72.7% |
| Acrux (ASX:ACR) | 19.5% | 91.8% |
| AVA Risk Group (ASX:AVA) | 15.7% | 77.3% |
| IperionX (ASX:IPX) | 17.5% | 67.8% |
| Pointerra (ASX:3DP) | 20.8% | 126.4% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| Plenti Group (ASX:PLT) | 12.8% | 120.1% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
| Findi (ASX:FND) | 34.8% | 112.9% |
Here we highlight a subset of our preferred stocks from the screener.
Alpha HPA
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alpha HPA Limited is a specialty metals and technology company with a market capitalization of A$1.04 billion.
Operations: The company's revenue segment includes the HPA First Project, generating A$0.04 million.
Insider Ownership: 12.6%
Revenue Growth Forecast: 105.7% p.a.
Alpha HPA demonstrates potential as a growth company with high insider ownership, despite some challenges. The company is expected to become profitable in the next three years, with forecasted earnings growth of 36.91% per year and revenue growth exceeding 100% annually, outpacing the Australian market average. However, it currently generates minimal revenue (A$44K) and has diluted shareholders over the past year. Recent events include an AGM discussing director re-elections and share rights issuance.
-
Take a closer look at Alpha HPA's potential here in our earnings growth report.
-
The valuation report we've compiled suggests that Alpha HPA's current price could be inflated.
PolyNovo
Simply Wall St Growth Rating: ★★★★★☆
Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.46 billion.
Operations: The company's revenue segment focuses on the development, manufacturing, and commercialization of the NovoSorb Technology, generating A$103.23 million.
Insider Ownership: 10.2%
Revenue Growth Forecast: 17.5% p.a.
PolyNovo's growth prospects are underscored by its forecasted earnings increase of 38.4% per year, surpassing the Australian market average. Despite recent substantial insider selling, the company remains a strong performer with revenue expected to grow at 17.5% annually. PolyNovo became profitable this year and trades at a notable discount to its estimated fair value. Recent developments include leadership changes and adoption of a new constitution, which may influence future strategic directions.